Endoscopic Results

VISIBLE IMPROVEMENTS IN THE ESOPHAGUS WERE OBSERVED^1,2

Improvements in EREFS total scores were observed at Weeks 16 and 52 with DUPIXENT^1,2

Reduction in EREFS
total score^d

Week 16
EoE KIDS-Part A
Secondary Endpoint

Week 52
EoE KIDS-Part B
Secondary Endpoint

LSM change from baseline

0
-1
-2
-3
-4
-5
-6

- 3.6 52% REDUCTION

DUPIXENT
(n=32)

P<0.0001

0 NO IMPROVEMENT

Placebo
(n=29)

3.8 POINT
IMPROVEMENT
at Week 16
vs placebo

- 4.9 71% REDUCTION

DUPIXENT
(n=26)

- 3.3 45% REDUCTION

Switch to
DUPIXENT
(n=13)

Thresholds for clinically meaningful changes in EREFS scores have not been established. Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.²

^dReductions indicate improvements in score.²

Endoscopic Reference Score (EREFS)

EREFS is a clinician-reported rating of the severity of 5 endoscopic features:
edema, rings, exudates, furrows, and strictures.⁶

LSM, least squares mean.

VISIBLE IMPROVEMENTS IN THE ESOPHAGUS WERE OBSERVED1,2

Endoscopic Reference Score (EREFS)

VISIBLE IMPROVEMENTS IN THE ESOPHAGUS WERE OBSERVED^1,2